Latest Breaking News On - Phase 1 loxo ras 20001 study nct04956640 - Page 1 : comparemela.com

Joshua K. Sabari, MD, discusses key findings from the phase 1 LOXO-RAS-20001 study of the KRAS G12C inhibitor LY3537982 in KRAS G12C–mutant advanced solid tumors.

Joshuak sabariGrossman school of medicineLangone health perlmutter cancer centerDepartment of medicinePerlmutter cancer centerNon small cell lung cancerPhase 1 loxo ras 20001 study nct04956640Kras g12c inhibitorKras g12c mutant advanced solid tumors